Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2022. The company is a development-stage specialty biopharmaceutical business focused on critical-care and oncology products; it reported no operating revenue.
Financial performance and position
| Metric | Three months ended March 31, 2022 | Six months ended March 31, 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.45 million | $8.91 million |
| General and administrative expense | $3.12 million | $6.01 million |
| Stock-based compensation expense | $1.02 million | $1.93 million |
| Net loss | $7.56 million | $16.79 million |
| Basic and diluted loss per share | $0.05 | $0.11 |
| Net cash used in operating activities | Not presented separately | $14.32 million |
At March 31, 2022, cash and cash equivalents were $55.76 million, down from $70.07 million at September 30, 2021. Working capital was approximately $54.2 million. Total assets were $127.79 million and total liabilities were $9.59 million. The company reported no outstanding notes payable; liabilities included $769,218 of operating lease obligations and a $4.99 million deferred tax liability. With no product revenue, profit and operating margins are not meaningful.
Changes versus prior comparable periods
- Second-quarter net loss increased $3.44 million year over year; six-month net loss increased $4.52 million.
- Six-month R&D expense rose $1.17 million, including $4.52 million of I/ONTAK development costs and higher Halo-Lido spending. Lower ARDS spending, including the prior-year $5 million Novellus license charge, partly offset increases.
- Six-month G&A expense increased $2.03 million, and stock-based compensation increased $1.31 million, primarily reflecting employee, director and consultant costs and new option grants.
- Operating cash use was $14.32 million versus $13.84 million in the prior-year six-month period. There were no financing cash inflows in the current period; the prior-year period included $103.67 million of equity and warrant-exercise proceeds.
Outlook, risks and other notable items
- Management estimated available cash would fund operations through March 2023 and said additional capital would be needed to support operations beyond then. It cautioned there is no assurance financing will be available on acceptable terms or in time.
- Management expected R&D expense to continue increasing in fiscal 2022 as it advances Mino-Lok and I/ONTAK, Halo-Lido, ARDS and Mino-Wrap.
- The FDA issued a Study May Proceed letter for Halo-Lido’s Phase 2b study; the company expected the study to begin in the quarter ending June 30, 2022. After quarter-end, the company reported I/ONTAK Phase 3 topline results and anticipated filing a BLA in the second half of 2022. These are forward-looking statements, not assured outcomes.
- Product development, regulatory approval, commercialization and future financing are key uncertainties. The filing describes substantial potential license-related milestone, royalty and cost obligations, including I/ONTAK development and commercial milestones and NoveCite milestones of up to $51 million.
- The filing reported no legal proceedings and no change in risk factors from the company’s December 2021 Form 10-K. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the cash runway estimate through March 2023 remains realistic given operating cash burn and planned clinical spending.
- Regulatory and clinical progress for I/ONTAK and Mino-Lok, including the status and timing of any BLA filings or approvals.
- Availability, timing and potential dilution of future financing; at March 31, 2022, 40.02 million warrants were outstanding, alongside 9.32 million options outstanding and 3.97 million shares available for future plan grants.
- The scale and timing of contingent license payments, royalties and development costs if product milestones are achieved.